1. A pharmaceutical composition of nanoparticles, said nanoparticles comprise a shell portion in which the predominant positively charged chitosan core portion which comprises one negatively charged substrate conjugate PGA-chelator, wherein said negatively charged substrate at least partially neutralized with a portion of said positively charged chitosan in the core parts of at least one bioactive agent is loaded into said nanoparticles, and optionally the compound with zero zaryadom.2. The pharmaceutical composition of claim 1 wherein said nanoparticles have an average particle size of from about 50 to 400 nm.3. A pharmaceutical composition according to claim 1, wherein said chitosan is N-trimetilhitozana, EDTA-chitosan, low molecular weight chitosan, chitosan derivatives or their kombinatsii.4. A pharmaceutical composition according to claim 1, wherein said nanoparticles are formed by a simple method and moderate ionic zhelirovaniya.5. A pharmaceutical composition according to claim 1, wherein said nanoparticles are formulated into tablet, pill or chewing massy.6 configuration. A pharmaceutical composition according to claim 5, wherein said tablet or bolus covered with an enteric pokrytiem.7. A pharmaceutical composition according to claim 1, wherein said nanoparticles are encapsulated in kapsulu.8. A pharmaceutical composition according to claim 7, wherein said capsule further comprises a pharmaceutically acceptable carrier, diluent or napolnitel.9. A pharmaceutical composition according to claim 7, wherein said capsule further comprises at least a solubilizer, a bubbling agent or emulgator.10. pharmaceuticals to1. Фармацевтическая композиция наночастиц, указанные наночастицы включают оболочечную часть, в которой преобладает положительно заряженный хитозан, сердцевинную часть, которая включает один отрицательно заряженный субстрат конъюгата PGA-комплексон, где указанный отрицательно заряженный субстрат по меньшей мере частично нейтрализован частью указанного поло
